logo
Alarming Rise in Early-Onset GI

Alarming Rise in Early-Onset GI

Medscape3 days ago
Early-onset gastrointestinal (GI) cancers diagnosed before age 50 are rising at alarming rates worldwide, underscoring the need for enhanced prevention strategies and early detection, said the authors of a JAMA review .
In the US, early-onset GI cancers are increasing faster than any other type of early-onset cancer, including breast cancer. The trend is not limited to colorectal cancer (CRC). Gastric, pancreatic, esophageal, as well as many biliary tract and appendix cancers, are also on the rise in young adults, Kimmie Ng, MD, MPH, and Thejus Jayakrishnan, MD, both with Dana-Farber Cancer Institute, Boston, noted in their article.
The increase in early-onset GI cancers follows a 'birth cohort effect,' with generational variation in risk, suggesting a potential association with changes in environmental exposures, Ng explained in an accompanying JAMA podcast.
All these GI cancers link strongly to multiple modifiable risk factors, and it is a 'top area of investigation to determine exactly what environmental exposures are at play,' Ng added.
For many of these GI cancers, obesity has been the 'leading hypothesis' given that rising rates seem to parallel the increase in incidence of these early-onset GI cancers, Ng explained.
'But we also have evidence, particularly strong for colorectal cancer, that dietary patterns, such as consuming a Western diet, as well as sedentary behavior and lifestyles seem to be associated with a significantly higher risk of developing these cancers at an age under 50,' Ng said.
Rising Incidence
Globally, among early-onset GI cancers reported in 2022, CRC was the most common (54%), followed by gastric cancer (24%), esophageal cancer (13%), and pancreatic cancer (9%).
In the US in 2022, 20,805 individuals were diagnosed with early-onset CRC, 2689 with early-onset gastric cancer, 2657 with early-onset pancreatic cancer, and 875 with early-onset esophageal cancer.
Since the mid-1990s, CRC among adults of all ages in the US declined by 1.3%-4.2% annually but early-onset CRC increased by roughly 2% per year in both men and women, and currently makes up about 14% of all CRC cases.
Early-onset pancreatic cancer and esophageal cancer each currently make up about 5% of all cases of these cancers in the US.
Between 2010 and 2019, the number of newly diagnosed cases of early-onset GI cancers rose by nearly about 15%, with Black, Hispanic, Indigenous ancestry, and women disproportionately affected, Ng and coauthors noted in a related review published in the British Journal of Surgery .
Modifiable and Nonmodifiable Risk Factors
Along with obesity and poor diet, other modifiable risk factors for early-onset GI cancers include sedentary lifestyle, cigarette smoking, and alcohol consumption.
Nonmodifiable risk factors include family history, hereditary cancer syndromes such as Lynch syndrome and inflammatory bowel disease.
Roughly 15%-30% of early-onset GI cancers have pathogenic germline variants in genes such as DNA mismatch repair genes and BRCA 1/2.
All individuals with early-onset GI cancers should undergo germline and somatic genetic testing to guide treatment, screen for other cancers (eg, endometrial cancer in Lynch syndrome), and assess familial risk, Ng and Jayakrishnan advised.
Treatment Challenges
Treatment for early-onset GI cancers is generally similar to later-onset GI cancers and prognosis for patients with early-onset GI cancers is 'similar to or worse' than that for patients with later-onset GI cancers, highlighting the need for improved methods of prevention and early detection, the authors said.
Ng noted that younger cancer patients often face more challenges after diagnosis than older patients and benefit from multidisciplinary care, including referral for fertility counseling and preservation if appropriate, and psychosocial support.
'It is very difficult and challenging to receive a cancer diagnosis no matter what age you are, but when a person is diagnosed in their 20s, 30s, or 40s, there are unique challenges,' Ng said.
Studies have documented 'much higher levels of psychosocial distress, depression and anxiety' in early-onset cancer patients, 'and they also often experience more financial toxicity, disruptions in their education as well as their career and there may be fertility concerns,' Ng added.
Diagnostic Delays and Screening
Currently, screening is not recommended for most early-onset GI cancers — with the exception of CRC, with screening recommended for average-risk adults in the US starting at age 45.
Yet, despite this recommendation, fewer than 1 in 5 (19.7%) US adults aged 45-49 years were screened in 2021, indicating a significant gap in early detection efforts.
High-risk individuals, such as those with Lynch syndrome, a first-degree relative with CRC, or advanced colorectal adenoma, should begin CRC screening earlier, at an age determined by the specific risk factor.
'Studies have shown significant delays in diagnosis among younger patients. It's important that prompt diagnosis happens so that these patients do not end up being diagnosed with advanced or metastatic stages of cancer, as they often are,' Ng said.
'Screening adherence is absolutely critical,' co-author Jayakrishnan added in a news release.
'We have strong evidence that colorectal cancer screening saves lives by reducing both the number of people who develop colorectal cancer and the number of people who die from it. Each missed screening is a lost opportunity to detect cancer early when it is more treatable, or to prevent cancer altogether by identifying and removing precancerous polyps,' Jayakrishnan said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Option Care Health, Inc. (OPCH): A Bull Case Theory
Option Care Health, Inc. (OPCH): A Bull Case Theory

Yahoo

time15 minutes ago

  • Yahoo

Option Care Health, Inc. (OPCH): A Bull Case Theory

We came across a bullish thesis on Option Care Health, Inc. on Brian's Substack by Brian Flasker. In this article, we will summarize the bulls' thesis on OPCH. Option Care Health, Inc.'s share was trading at $29.35 as of July 31st. OPCH's trailing and forward P/E were 23.29 and 19.65, respectively according to Yahoo Finance. A home infusion nurse in full PPE gown delivering treatments to a patient in their own home. Option Care Health (OPCH) has evolved into the dominant independent provider of home and alternate site infusion services in the U.S., originating from Madison Dearborn Partners' 2015 acquisition of Walgreens Infusion Services. The 2019 reverse merger with BioScrip and full divestiture by Walgreens and MDP by 2023 paved the way for OPCH to operate with full independence. Led by CEO John Rademacher and CFO Michael Shapiro, both with substantial equity stakes, OPCH has built a national infrastructure of 91 pharmacies and 99 infusion suites, covering 96% of the U.S. population. The company's integrated model provides cost-effective, high-quality infusion therapies in outpatient and home settings, capitalizing on a healthcare trend shifting treatments away from costly hospitals. This platform serves over 1,400 contracts with 800+ partners, including all top 10 national insurers. Acute therapies, though operationally complex, act as a competitive wedge, while chronic therapies anchor long-term recurring revenues. OPCH's mix—75% chronic, 25% acute—combined with a focus on generics and biosimilars, ensures resilience against pricing volatility. With its Advanced Practitioner (AP) model, OPCH is pushing clinical boundaries, managing more complex therapies in lower-cost settings and enhancing utilization of its already-built infrastructure. Only ~50% of its infusion suite capacity is currently utilized, leaving ample runway for capital-light growth. Despite industry concerns like drug pricing reforms and labor shortages, OPCH's embedded relationships, clinical capabilities, and scalable model offer strong visibility into cash flow and earnings. Trading at ~15.4x 2025 owner earnings with a 17.4% expected IRR, OPCH represents a high-quality compounder with an entrenched moat and significant upside. Previously, we covered a bullish thesis on Chemed Corporation by 310 Value in April 2025, which highlighted the durability of its earnings, temporary volatility in its subsidiaries, and disciplined share repurchases. The company's stock price has depreciated by approximately 29% since our coverage. This is because temporary segment headwinds persisted longer than expected. The thesis still stands as Chemed's core fundamentals remain intact. Brian Flasker shares a similar view but emphasizes OPCH's capital-light model and payer-aligned infrastructure. Option Care Health, Inc. is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 40 hedge fund portfolios held OPCH at the end of the first quarter, which was 40 in the previous quarter. While we acknowledge the potential of OPCH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Canada Wildfires Worsen Air Quality Across Midwest, Northeast US
Canada Wildfires Worsen Air Quality Across Midwest, Northeast US

Bloomberg

time5 hours ago

  • Bloomberg

Canada Wildfires Worsen Air Quality Across Midwest, Northeast US

Smoke and grit from hundreds of forest fires have spread across large parts of Canada and the northern US, sending air quality across the Midwest and northeast US and Toronto to unhealthy levels. Air quality deteriorated to moderate in Chicago early Sunday with some areas unhealthy for sensitive groups, and to unhealthy in Milwaukee and downtown Toronto, Canada's largest city, according to Alerts were raised across Canada from the Northwest Territories to Quebec, as well as in 10 US states from Minnesota to Maine, including Upstate and western New York.

HHS: How we're fixing the organ transplant system that betrayed America
HHS: How we're fixing the organ transplant system that betrayed America

CNN

time7 hours ago

  • CNN

HHS: How we're fixing the organ transplant system that betrayed America

EDITOR'S NOTE: Thomas Engels is the administrator of the Health Resources and Services Administration at the US Department of Health and Human Services. Organ donation can be a profound last gift of life. I think about the future my grandson will inherit, especially when it comes to something as urgent and deeply personal as organ donation or transplant. If he or someone he loves needs an organ transplant, I want him to know the system is safe, fair and worthy of his trust. Sadly, our US Department of Health and Human Services investigation of the organ transplant system has revealed everyone's worst nightmare: a systemic disregard for the sanctity of life. We found numerous cases of medical providers starting the organ donation process on living patients. In response, we have threatened to shut down a large organ procurement organization unless it implements our corrective action requirements. We have also imposed strict reporting protocols for the organ transplant system and required that families and hospitals receive clear, complete information about the donation process. How did the organ transplant system fail to protect some of our most vulnerable Americans? It operated behind closed doors for decades, dominated by a single private contractor. Too many patients waited for answers that never came, and families whose loved ones' organs were pursued while still alive were left with nowhere to turn when such atrocities occurred. Only a sick system prioritizes profit over patients. That ended thanks to the leadership of President Donald Trump and HHS Secretary Robert F. Kennedy Jr. At the Health Resources and Services Administration (HRSA), we are undertaking a sweeping overhaul of the Organ Procurement and Transplantation Network (OPTN), the entity legally responsible for managing the organ waitlist and allocation nationwide. Our reforms are rooted in two fundamental truths: Patient safety is not optional, and every life is sacred. For far too long, patients, hospital staff or grieving families were forced to report serious safety concerns and misconduct to the very contractor managing the system. This left families unheard, frustrated or even silenced. That era is over. Now, under our new reforms, those concerns can come directly to the regulator HRSA. We brought federal oversight into the heart of the process, making it clear there will be no compromise on safety and accountability. We've also proposed new data requirements for organ procurement organizations (OPOs), requiring full documentation of every step in the donation process, from contact with hospitals to interactions with donor families. These reforms aren't just about performance tracking. They're about restoring safety and dignity to a system that lost sight of both. And when horrifying failures come to light, like the shocking case in Kentucky in which organ procurement was nearly performed on a patient who showed signs of life, we act immediately. For the first time, HRSA issued a corrective action plan to an OPO, and we will not hesitate to do it again. No American should ever have to wonder whether their life will be treated with reverence at the hospital. The systemic failures weren't just operational — they were structural. For nearly 40 years, OPTN was governed by a single private entity: the United Network for Organ Sharing (UNOS). We ended a monopoly that suppressed innovation, enabled conflicts of interest and delayed reform. HRSA conducted a historic national election to establish an independent OPTN Board of Directors. This new board includes transplant surgeons, living donors, organ recipients and advocates, bringing a range of expertise and experience to the forefront of reform. We are also modernizing the transplant system by expanding the pool of best-in-class vendors to expand the capacity and performance of the system. With bipartisan support, HRSA now has the authority to directly collect OPTN registration fees from transplant hospitals, helping sustain long-term reforms and reduce reliance on any single contractor. Our work is informed by conversations with transplant surgeons, patients, donor families, advocates and hospital staff. These voices have made one thing abundantly clear: Change cannot wait. Secretary Kennedy has demanded accountability across HHS, and President Trump has shown unwavering commitment to ending complacency in systems that cost lives. The old system operated behind closed doors. We opened them up. We are building a system that is ethical, transparent and centered on the sacred sanctity of life. There is more work to do, but we are making progress quickly, just like the rest of the Trump administration. We will not rest until every registered organ donor, patient and family have confidence in our nation's transplant system. Because that's what Americans deserve and what every life demands.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store